Cyanosis surgery: Difference between revisions
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
== Recommendation for surgery in [[cyanotic heart disease]] ==<ref name="StoutDaniels2019">{{cite journal|last1=Stout|first1=Karen K.|last2=Daniels|first2=Curt J.|last3=Aboulhosn|first3=Jamil A.|last4=Bozkurt|first4=Biykem|last5=Broberg|first5=Craig S.|last6=Colman|first6=Jack M.|last7=Crumb|first7=Stephen R.|last8=Dearani|first8=Joseph A.|last9=Fuller|first9=Stephanie|last10=Gurvitz|first10=Michelle|last11=Khairy|first11=Paul|last12=Landzberg|first12=Michael J.|last13=Saidi|first13=Arwa|last14=Valente|first14=Anne Marie|last15=Van Hare|first15=George F.|title=2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines|journal=Circulation|volume=139|issue=14|year=2019|issn=0009-7322|doi=10.1161/CIR.0000000000000603}}</ref> | == Recommendation for surgery in [[cyanotic heart disease]] == | ||
The table shows indications for surgery in [[cyanotic congenital heart disease]] according to 2018 AHA/ACC Guideline:<ref name="StoutDaniels2019">{{cite journal|last1=Stout|first1=Karen K.|last2=Daniels|first2=Curt J.|last3=Aboulhosn|first3=Jamil A.|last4=Bozkurt|first4=Biykem|last5=Broberg|first5=Craig S.|last6=Colman|first6=Jack M.|last7=Crumb|first7=Stephen R.|last8=Dearani|first8=Joseph A.|last9=Fuller|first9=Stephanie|last10=Gurvitz|first10=Michelle|last11=Khairy|first11=Paul|last12=Landzberg|first12=Michael J.|last13=Saidi|first13=Arwa|last14=Valente|first14=Anne Marie|last15=Van Hare|first15=George F.|title=2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines|journal=Circulation|volume=139|issue=14|year=2019|issn=0009-7322|doi=10.1161/CIR.0000000000000603}}</ref> | |||
'''<span style="font-size:85%">'''Abbreviations:''' | '''<span style="font-size:85%">'''Abbreviations:''' |
Revision as of 05:14, 28 October 2020
Cyanosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cyanosis surgery On the Web |
American Roentgen Ray Society Images of Cyanosis surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Recommendation for surgery in cyanotic heart disease
The table shows indications for surgery in cyanotic congenital heart disease according to 2018 AHA/ACC Guideline:[1]
Abbreviations:
TGA: Transposition of great arteries;
PDA: Patent ductus arteriosus ;
ASD: Atrial septal defect;
VSD: Ventricular septal defect;
TAPVC: Total anomalous pulmonary venous connection;
TOF: Tetralogy of fallot;
CCTGA: Congenitally corrected transposition of the great arteries;
Recommendation for surgery in cyanotic congenital heart disease |
Indications for repair of a scimitar vein in Anomalous pulmonary venous connection (TAPVC) (Class I, Level of Evidence B ): |
❑ Decreased functional capacity |
Indications for surgery in Anomalous Pulmonary Venous Connections (TAPVC)(Class 2a, Level of Evidence B) : |
❑ Asymptomatic adults with right ventricle volume overload |
Indications for surgery repair or reoperation in Ebstein anomaly : (Class I, Level of Evidence B) |
❑ Significant tricuspid regurgitation in the presence of the following: |
Indications for surgery repair or reoperation in Ebstein anomaly:(Class 2a, Level of Evidence B) |
❑ Significant tricuspid regurgitation in the presence of the following: |
Indication for Glenn anastomousis at the time of repair in Ebstein anomaly : (Class 2b, Level of Evidence B) |
❑ Severe right ventricle dilation |
Indication for pulmonary valve replacement ( surgical or percutaneous in Tetralogy of fallot (Class I, Level of Evidence B): |
❑ Symptomatic Moderate to severe pulmonary regurgitation after repaired TOF in which symptoms can not be explained otherwise. |
Indication for Pulmonary valve replacement ( surgical or percutaneous in Tetralogy of fallot : (Class 2a, Level of Evidence B) |
❑ Asymptomatic moderate to severe pulmonary regurgitation after repaired TOF |
Indication for Tricuspid valve replacement in CCTGA : (Class I, Level of Evidence B) |
❑ Symptomatic severe tricuspid regurgitaion accompanied by preserved or mildly systolic dysfunction of systemic ventricle |
Indication for Tricuspid valve replacement in CCTGA : (Class 2a, Level of Evidence C) |
❑ Asymptomatic severe tricuspid regurgitation accompanied by mildly dilated systemic ventricle |
Indication for conduit intervention/replacement in CCTGA : (Class 2b, Level of Evidence B) |
❑ Symptomatic subpulmonary left ventricle to pulmonary artery conduit dysfunction |
References
- ↑ Stout, Karen K.; Daniels, Curt J.; Aboulhosn, Jamil A.; Bozkurt, Biykem; Broberg, Craig S.; Colman, Jack M.; Crumb, Stephen R.; Dearani, Joseph A.; Fuller, Stephanie; Gurvitz, Michelle; Khairy, Paul; Landzberg, Michael J.; Saidi, Arwa; Valente, Anne Marie; Van Hare, George F. (2019). "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". Circulation. 139 (14). doi:10.1161/CIR.0000000000000603. ISSN 0009-7322.